Author

Christopher Alexander French

Brigham and Women's HospitalORCID 0000-0002-7434-4987Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Research Focus:drug response / drug discovery· 2 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1

Frequent Co-Authors

Alex RubinsteyniD· 1 shared B. V. Vincent· 1 shared Benjamin K. Eschle· 1 shared Brandon A. PriceiD· 1 shared Brian A. KuhlmaniD· 1 shared Brittaney A. LeeperiD· 1 shared Daesik KimiD· 1 shared Dustin Rogers· 1 shared

Activity by Year

2025-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 13 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alex RubinsteynORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

BET BD2 inhibition facilitates SPOP-mediated degradation of chromatin-associated BRD4/BRD4-NUT, a therapeutic vulnerability in NUT carcinoma

Kathleen Bates, Hoang Nguyen, Kyle P. Eagen, Julianna Huang, Prafulla C. Gokhale, Brittaney A. Leeper, Benjamin K. Eschle, Stacey T Gray, Krupa Sampat, Taylor R Durall, Jia Luo, Geoffrey Ira Shapiro, Steven J. Ferrara, Jacob Gillis, Dustin Rogers, , Christopher Alexander French

The paper shows that selective inhibition of BRD4-BD2 promotes SPOP-mediated degradation of BRD4/BRD4-NUT in NUT carcinoma, leading to better therapeutic outcomes than pan-BET inhibition.

bioRxiv · Aug 19, 2026 · PreprintCancer Biology

Shared PRAME Epitopes are T-Cell Targets in NUT Carcinoma

Jeffrey Lee Jensen, Sara K. Peterson, Maria J. Sambade, Jessica Alley, Shawn Yu, Tomoaki Kinjo, Sarah Bennett, Steven P. Vensko II, Mitra Shabrang, Johnathan D. DeBetta, Julie K. Geyer, Brandon A. Price, Kwangok P. Nickel, Randall J. Kimple, Rishi Sury Kotecha, , B. V. Vincent

This study identifies PRAME as a therapeutic target in NUT carcinoma, showing its high expression and susceptibility to T-cell mediated cytotoxicity via PRAME epitopes presented by HLA Class I molecules.

Journal for ImmunoTherapy of Cancer · Feb 1, 2026Peer-reviewedCancer Biology

CRISPR-Induced NUT Suppression Promotes Differentiation and Enhances Trop2-Targeted Immunocytokine Response in NUT Carcinoma

Juyoung Choi, Daesik Kim, Joo Youn Oh, Hee Geon Park, Hwa Lin Yi, Yurimi Lee, Hoyeon Jeong, Jiyoung Song, Minjung Sung, Eun Sol Chang, Kyungsoo Jung, Saehyung Lee, Young Kee Shin, Se‐Hoon Lee, Christopher Alexander French, , Yoon‐La Choi

This study shows that CRISPR suppression of NUTM1 promotes differentiation and increases TROP2 in NUT carcinoma cells, enhancing immunocytokine response and improving clinical outcomes.

bioRxiv · Oct 28, 2025 · PreprintCancer Biology